RxDoctor Payments Data

Julie Asari, MD

Internal Medicine · Honolulu, HINPI 1174520431

Payments from drug & device makers

$694in general payments, 2019–2025

Across 29 payments — averaging $23.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$215
  • Lilly USA, LLC$132
  • Bayer$68
  • Amgen$50
  • Amarin Pharma, Inc.$46
  • GSK$29
  • plus $154 from 7 others

What the payments were for

  • Food & beverage$67898%
  • Education$162%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$694 in reported general payments places this provider in the 65th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$128,719
Medicare patients
291
Services billed
1,041

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$142,472
FarxigaDapagliflozin Propanediol66$99,750
OzempicSemaglutide58$85,094
ProliaDenosumab45$76,716
RybelsusSemaglutide34$71,097
TrulicityDulaglutide30$57,808
MounjaroTirzepatide22$39,412
VascepaIcosapent Ethyl22$20,017
JanuviaSitagliptin Phosphate12$19,160
Repatha SureclickEvolocumab14$18,899
KerendiaFinerenone16$18,005
Atorvastatin Calcium532$14,468
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$11,824
Candesartan Cilexetil108$8,354
Rosuvastatin Calcium177$8,294

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$215$156,19092 claims
AstraZenecaFarxiga$23$99,75066 claims
Lilly USA, LLCTrulicity, Mounjaro$132$97,21952 claims
AmgenProlia$50$76,71645 claims
BayerKerendia$68$18,00516 claims
GSKAnoro Ellipta$29$11,82415 claims
AbbVieSynthroid$25$1,30130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Honolulu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →